RE:Stocktree, this is from MD &D March 27, 2014, page 4-5Sorry Josh, but as I read that, no 10% MB was sated to be achieved. It only speak about the initial goals of the trial and, based on the interim data, how many patients would be required to prove such an improvement.
On the rest of your post, I'll have to look at it more closely later today. But on your theory about the timing of the treatment, if we rely on the company's statements, we were told that the treatment proved to be more beneficial for sicker patients, so...
In a sense, even if the trial had been the success they were looking for (20%MB), we could se an unethical dimension to it, but only to a certain point, and not unlike what any other trial could be associated with. But since it was considered unproven, giving patients the SOC and administrating them the PMX treatment once they reached 3 organ failure would not have been unethical, since it only gave them an additional chance at survival.
Unless I didn't get part of your argument. I have to say, I am pretty unwinded by all this affair and not proud about my lack of digging and blind trust in vague statements.